Cargando…
Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report
RATIONALE: The pathogenesis and progression of lung cancer is a complicated process in which many genes take part. But molecular gene testing is typically only performed in advanced-stage non-squamous non-small-cell lung cancer (NSCLC). The value of tyrosine kinase inhibitors (TKI) administration is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348162/ https://www.ncbi.nlm.nih.gov/pubmed/28272214 http://dx.doi.org/10.1097/MD.0000000000006221 |
_version_ | 1782514183237009408 |
---|---|
author | Ding, Xingchen Wang, Linlin Liu, Xijun Sun, Xindong Yu, Jinming Meng, Xue |
author_facet | Ding, Xingchen Wang, Linlin Liu, Xijun Sun, Xindong Yu, Jinming Meng, Xue |
author_sort | Ding, Xingchen |
collection | PubMed |
description | RATIONALE: The pathogenesis and progression of lung cancer is a complicated process in which many genes take part. But molecular gene testing is typically only performed in advanced-stage non-squamous non-small-cell lung cancer (NSCLC). The value of tyrosine kinase inhibitors (TKI) administration is not widely recognized with respect to early-stage NSCLC. PATIENT CONCERNS: Here, we present a case of a man, heavy smoker who initially presented with stage IA lung adenocarcinoma (LADC). Three years after a lung lobectomy, he was diagnosed with advanced lung squamous cell carcinoma (SCC), according to laboratory, imaging, and pathological examinations. DIAGNOSES: The case initially had an early-stage LADC with an L858R epidermal growth factor receptor (EGFR) mutation. A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery. INTERVENTIONS: The comprehensive therapy we utilized, including surgical resection for the early-stage lesion and GP chemotherapy and local radiotherapy as the first line therapy along with gefitinib maintenance treatment for the advanced metachronous second primary tumors (MST). OUTCOMES: The synthetical therapy, have resulted in our patient with remaining alive and progression free for 4.5 years. LESSONS: This case suggests that changes in molecular pathology should be monitored closely throughout cancer progression to guide personalized therapy and improve prognosis. We further review administration of TKI to early-stage NSCLC and to the metachronous second primary tumors (MST) in survivors. |
format | Online Article Text |
id | pubmed-5348162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-53481622017-03-22 Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report Ding, Xingchen Wang, Linlin Liu, Xijun Sun, Xindong Yu, Jinming Meng, Xue Medicine (Baltimore) 5700 RATIONALE: The pathogenesis and progression of lung cancer is a complicated process in which many genes take part. But molecular gene testing is typically only performed in advanced-stage non-squamous non-small-cell lung cancer (NSCLC). The value of tyrosine kinase inhibitors (TKI) administration is not widely recognized with respect to early-stage NSCLC. PATIENT CONCERNS: Here, we present a case of a man, heavy smoker who initially presented with stage IA lung adenocarcinoma (LADC). Three years after a lung lobectomy, he was diagnosed with advanced lung squamous cell carcinoma (SCC), according to laboratory, imaging, and pathological examinations. DIAGNOSES: The case initially had an early-stage LADC with an L858R epidermal growth factor receptor (EGFR) mutation. A subsequent advanced SCC bearing EGFR L858R/T790M mutations occurred 3 years after surgery. INTERVENTIONS: The comprehensive therapy we utilized, including surgical resection for the early-stage lesion and GP chemotherapy and local radiotherapy as the first line therapy along with gefitinib maintenance treatment for the advanced metachronous second primary tumors (MST). OUTCOMES: The synthetical therapy, have resulted in our patient with remaining alive and progression free for 4.5 years. LESSONS: This case suggests that changes in molecular pathology should be monitored closely throughout cancer progression to guide personalized therapy and improve prognosis. We further review administration of TKI to early-stage NSCLC and to the metachronous second primary tumors (MST) in survivors. Wolters Kluwer Health 2017-03-10 /pmc/articles/PMC5348162/ /pubmed/28272214 http://dx.doi.org/10.1097/MD.0000000000006221 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 5700 Ding, Xingchen Wang, Linlin Liu, Xijun Sun, Xindong Yu, Jinming Meng, Xue Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title | Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title_full | Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title_fullStr | Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title_full_unstemmed | Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title_short | Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report |
title_sort | genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (nsclc) patients and survivors with metachronous second primary tumor (mst): a case report |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348162/ https://www.ncbi.nlm.nih.gov/pubmed/28272214 http://dx.doi.org/10.1097/MD.0000000000006221 |
work_keys_str_mv | AT dingxingchen geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport AT wanglinlin geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport AT liuxijun geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport AT sunxindong geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport AT yujinming geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport AT mengxue geneticcharacterizationdrivespersonalizedtherapyforearlystagenonsmallcelllungcancernsclcpatientsandsurvivorswithmetachronoussecondprimarytumormstacasereport |